Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Baxter
Teva
Dow
Chinese Patent Office
US Army
Merck
US Department of Justice
Queensland Health

Generated: April 19, 2018

DrugPatentWatch Database Preview

DEPAKOTE Drug Profile

« Back to Dashboard

Which patents cover Depakote, and when can generic versions of Depakote launch?

Depakote is a drug marketed by Abbvie and Abbott and is included in four NDAs. There are six patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in DEPAKOTE is divalproex sodium. There are seventeen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
Drug patent expirations by year for DEPAKOTE
Synonyms for DEPAKOTE
133299-66-8
644VL95AO6
76584-70-8
99-66-1 (Parent)
A838751
AB01568255_01
AB2000231
Abbott 50711
Abbott-50711
AC1Q1V4Q
AC1Q1VPW
AKOS015895200
AN-6581
API0002433
AS-17254
C-19234
C16H31NaO4
CC-27204
CHEBI:4667
CHEMBL2105613
D00304
D03LGY
Delepsine
Depacon (TN)
Depakote (TN)
Depakote CP
Depakote ER
Depakote ER (TN)
Depakote Sprinkle
Depakote;Epival
Divalproate
divalproex
DIVALPROEX SODIUM
Divalproex sodium (USP)
Divalproex sodium [USAN:USP]
Divalproex sodium [USAN]
Divalproex sodium salt
Divalproex sodium, Depakote, Epival
Divalproexsodium
DTXSID70227388
Epilex
Epival
Epival (TN)
Ergenyl Chrono (TN)
FT-0625375
HMS3651C17
I06-0339
LS-101863
MolPort-006-167-562
MSRILKIQRXUYCT-UHFFFAOYSA-M
Natrium hydrogen bis(2-propylvalerat)
OR339103
Pentanoic acid, 2-propyl-, sodium salt (2:1)
pentanoic acid, 2-propyl-, sodium salt(2:1)
potassium valproic acid dipropylacetate
s1703
SCHEMBL40996
Semisodium Valproate
Sodium 2-propylpentanoate 2-propylpentanoic acid
sodium 2-propylpentanoate--2-propylpentanoic acid (1:1)
Sodium 2-propylpentanoate-2-propylpentanoic acid (1:1)
Sodium divalproate
Sodium hydrogen bis(2-propylpentanoate)
Sodium hydrogen bis(2-propylvalerate)
Sodium hydrogen bis(2-propylvalerate), oligomer
Sodium hydrogen divalproate
sodium valproic acid valproate
sodium; 2-propylpentanoate; 2-propylpentanoic acid
Sprinkle
U058
UNII-644VL95AO6
Valance (TN)
Valcote
Valdisoval
Valparin
Valproate semisodique
Valproate semisodique [French]
Valproate semisodium
Valproate semisodium (INN)
Valproate semisodium [INN]
Valproato semisodico
Valproato semisodico [Spanish]
Valproatum seminatricum
Valproatum seminatricum [Latin]
Valproic acid semisodium salt (2:1)
Zalkote. (TN)

US Patents and Regulatory Information for DEPAKOTE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DEPAKOTE divalproex sodium CAPSULE, DELAYED REL PELLETS;ORAL 019680-001 Sep 12, 1989 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-002 Mar 10, 1983 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for DEPAKOTE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-001 Mar 10, 1983 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie DEPAKOTE divalproex sodium CAPSULE, DELAYED REL PELLETS;ORAL 019680-001 Sep 12, 1989 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DEPAKOTE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2005-02-08
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 2004-05-03

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Citi
Mallinckrodt
Daiichi Sankyo
Merck
Fuji
Fish and Richardson
Farmers Insurance
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.